A newly published clinical study in the Journal of Functional Biomaterials evaluates the safety and efficacy of Innovyal Regenerative Action, an injectable hydrogel developed with LOUNA’s proprietary Boost & Shield Technology. The formulation combines polynucleotides (PN), hyaluronic acid (HA), and niacinamide (vitamin B3) within a single injectable device designed to improve overall skin quality through regenerative stimulation.
The prospective, open-label clinical trial enrolled 42 female subjects (mean age 45 years, Fitzpatrick phototypes II–V) who received a single injection session in the cheek area. Efficacy was evaluated at baseline, week 2, and week 6 using both subjective (GAIS) and objective instrumental assessments (Antera 3D®, Cutometer®, Corneometer®, Dermascan®).
As regenerative aesthetics continues to evolve, there is growing interest in injectable solutions capable of addressing multiple biological aspects of skin aging simultaneously.
Innovyal Regenerative Action was specifically developed around this concept, combining three complementary active components:
The study investigated the clinical performance of this triple-combination injectable following a single treatment session, using both objective instrumental analysis and subjective patient evaluations.
The publication reports statistically significant improvements across all monitored parameters.
Skin roughness was significantly reduced as early as two weeks after treatment and continued to improve through week six, reflecting enhanced skin texture and overall radiance.
Hydration levels increased by nearly 29% compared to baseline, while elasticity and firmness measurements demonstrated progressive and sustained improvement throughout the study period.
High-frequency ultrasound imaging further confirmed biological changes within the skin, showing increased dermal thickness and density after a single treatment session.
These findings suggest that the combined action of polynucleotides, hyaluronic acid, and niacinamide may contribute to both visible and measurable improvements in skin quality.
Clinical outcomes were supported by strong patient satisfaction scores.
Immediately after treatment, 100% of subjects were rated as improved according to the Global Aesthetic Improvement Scale (GAIS), with more than 95% still showing improvement six weeks later.
Patient questionnaires revealed progressive satisfaction over time:
The safety profile was favorable throughout the study, with no serious adverse events reported. Investigators also reported high satisfaction regarding product handling and injection performance.
This publication provides clinical evidence supporting the regenerative approach behind Innovyal Regenerative Actionand further strengthens LOUNA’s expertise in polynucleotide-based injectable technologies.
The study demonstrates that the synergistic combination of polynucleotides, hyaluronic acid, and niacinamide, delivered through the proprietary Boost & Shield Technology, can generate measurable improvements in multiple skin quality parameters after a single treatment session.
By combining advanced biomaterial engineering with clinically validated regenerative mechanisms, LOUNA continues to contribute to the development of evidence-based solutions designed to support long-term skin quality and tissue health.
Title: An Injectable Biopolymer Hydrogel Complex (PN/HA/B3) for Facial Skin Redensification and General Rejuvenation: Clinical Report on Device Safety and Efficacy
Authors: Porcello A, Lourenço K, Marques C, Raffoul W, Cerrano M, Applegate LA, Laurent AE
Published in: Journal of Functional Biomaterials (MDPI, 2026)
Browse our collection of scientific publications, clinical insights, industry news, and expert perspectives on skin regeneration, polynucleotides, and aesthetic longevity.